Go Deep
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -15,746 | -0.6 | -0.37 | -1.32 | 295.22 |
| Oct 2026 | -15,629 | -0.5 | -0.33 | -1.32 | 263.95 |
| Oct 2026 | -15,743 | -0.7 | -0.37 | -1.32 | 293.43 |
| Oct 2026 | -15,845 | -0.6 | -0.40 | -1.32 | 319.19 |
| Oct 2026 | -15,735 | -0.6 | -0.37 | -1.32 | 291.09 |
| Oct 2026 | -15,783 | -0.6 | -0.38 | -1.32 | 303.41 |
| Oct 2026 | -15,732 | -0.6 | -0.36 | -1.32 | 289.42 |
| Oct 2026 | -15,970 | -0.7 | -0.41 | -1.32 | 325.65 |
Armata Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | — | 0.0 | 0.0 | 0.0 |
| Net Profit | — | -115,346,000.0 | -124,298,000.0 | -26,675,000.0 |
| EPS | 2.0 | -3.2 | — | -0.7 |
Armata Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -173,799,000.0 | -18,916,000.0 | -69,045,000.0 | -36,917,000.0 | — |
| EPS | -4.8 | -0.5 | -1.9 | -1.1 | — |
Armata Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 76,882,000.0 | 86,437,000.0 | 98,363,000.0 | 95,834,000.0 | — |
| Total Liabilities | 295,478,000.0 | 134,456,000.0 | 130,428,000.0 | 59,754,000.0 | — |
| Total Equity | -218,596,000.0 | -48,019,000.0 | -32,065,000.0 | 36,080,000.0 | — |
Owes vs Owns
Armata Pharmaceuticals, Inc. owed $5.46 for every $1 it owned in Mar 2026, up from $0.62 in Dec 2022.
| Period | Mar 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 5.46× | 3.84× | 1.56× | 1.33× | 0.62× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Armata Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 11.3%Receivables 0.6%Fixed assets (tangible) 60.0%Intangible assets 17.9%Other assets 10.2%
How it's funded — Dec 2025
Short-term debt 1.5%Long-term debt 87.0%Other liabilities 11.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 8.7 | 9.3 | 13.5 | 14.9 |
| Receivables | 0.5 | 0.7 | 3.4 | 8.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 46.1 | 54.9 | 57.3 | 46.7 |
| Intangible assets | 13.7 | 13.7 | 13.7 | 13.7 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 7.9 | 7.7 | 10.5 | 12.1 |
| Liabilities & equity | ||||
| Short-term debt | 4.6 | 39.0 | 9.5 | 17.0 |
| Long-term debt | 256.9 | 55.4 | 82.3 | 31.8 |
| Payables | 0.9 | 0.8 | 1.6 | 1.7 |
| Other liabilities | 33.1 | 39.3 | 37.1 | 9.3 |
| Shareholders' equity | -218.6 | -48.0 | -32.1 | 36.1 |
| Net tangible assets | -232.3 | -61.8 | -45.8 | 22.3 |
Armata Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -25,763,000.0 | -37,551,000.0 | -47,423,000.0 | -32,481,000.0 | — |
| Investing Activities | -542,000.0 | -1,879,000.0 | -8,134,000.0 | -2,211,000.0 | — |
| Financing Activities | 25,612,000.0 | 34,958,000.0 | 53,988,000.0 | 44,016,000.0 | — |